# A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer

> **NCT06075758** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 175 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **OTHER:** ribociclib

## Key facts

- **NCT ID:** NCT06075758
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-07
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 175 (ACTUAL)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06075758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06075758, "A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT06075758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*